Introduction
As a primary sexual hormone, testosterone not only plays a key role in the primary sexual development and regulation of secondary male characteristics but is also responsible for the metabolism of glucose/lipid/proteins, growth of muscle, and adipogenesis [
1]. Testosterone has a variety of physiological target organs, such as the prostate, bone, muscle, brain, and peripheral nerves [
2]. Testosterone deficiency may be associated with metabolic syndrome, obesity, sexual dysfunction, impaired infertility, depression, bone/muscle mass loss, anaemia, diabetes, and sarcopenia [
3]. Testosterone is primarily bound to sex hormone binding protein (SHBG) and albumin and dissociate in tissue capillaries to generate free testosterone to exert androgenic activity [
4]. Testosterone binding to albumin is weak and can be reversed easily. Therefore free testosterone and albumin-bound testosterone are called bioavailable testosterone. A cohort study showed that low serum testosterone can increase the risk of prostate cancer. Patients with baseline testosterone below 3.85 ng/ml had greater chances of developing prostate cancer than those with high levels [
5]. However, whether testosterone levels are a risk factor or predictor of prostate cancer prognosis remains unclear. A case–control study suggested that high levels of circulating free testosterone may be associated with a reduced risk of lung cancer in postmenopausal never-smoking women [
6]. Another study suggested that premenopausal women with elevated serum testosterone levels have an increased risk of breast cancer [
7]. A meta-analyses demonstrated inverse associations between circulating levels of testosterone and colorectal/colon cancer risk [
8]. Although there are many researches on the association of indirect measures of testosterone exposure with the risk of cancer, studies on the causal role of testosterone levels in men’s cancers remain unclear.
Mendelian randomization (MR) is a method of using genetic variation arising from meiosis to investigate the causal relationship between exposure and complex outcomes. MR analysis depends on integrating genome-wide association study (GWAS) summary data [
9]. A genetic variable is valid in the MR analysis if it meets the following 3 assumptions: (i) the genetic variants are associated with exposure; (ii) the genetic variants are independent of confounders between exposure and outcomes, and (iii) the genetic variants only influence the outcome via exposure [
10]. Two-sample MR analysis refers to an MR analysis that includes a pair of exposures and outcomes from different (nonoverlapping) samples of the same underlying population. Many researchers have used Mendelian randomization to explore the role of endogenous testosterone in different diseases. Testosterone was shown to have a positive correlation with thromboembolism, heart failure, and myocardial infarction in men through a Mendelian randomization study by Luo [
11]. With genetic instruments from JMJD1C and SHBG regions, a two-sample Mendelian randomization study found that low levels of testosterone may cause gout and type II diabetes (T2D), while testosterone higher than normal levels may result in rheumatoid arthritis (RA) and depression [
12]. With the rapid development of large-scale GWAS, many MR studies have emerged that have explored the potential causal relationship between exposure and cancers, for example, elevated plasma HDL and LDL levels have been associated with increased breast cancer risk [
13] and type 2 diabetes mellitus (T2DM) have been associated with several cancers [
14].
This study used large-scale GWAS data to assess the potential causal associations of testosterone levels with 22 kinds of cancers in men through a two-sample MR study. This study helps to reveal testosterone’s genetic role in men’s cancer risk.
Discussion
This is the first two-sample MR analysis of the potential causality of men’s testosterone levels for a broad range of site-specific cancers. The results showed that BT level was significantly associated with a higher risk of prostate cancer; TT levels may be a suggestively protective factor for stomach cancer and pancreatic cancer. There was a suggestive association between TT level and increased risk of small intestine cancer as. We did not find significant evidence of the association of testosterone levels with other cancers.
Bioavailable testosterone is the part of testosterone that diffuses easily and plays important roles in different organs and systems. So it can better reflect the biological activity of testosterone than TT. As has been previously mentioned, testosterone, and testosterone deficiency has a significant impact on the overall quality of life. In the 1940s, Huggins and Hodges found that orchiectomy or estrogen therapy for metastatic prostate cancer patients can reduce testosterone secretion and reduce serum acid phosphatase activity and injection of androgens can increase acid phosphatase. Since then, testosterone was believed to promote prostate cancer cell growth and disease progression [
23]. Subsequently, more evidence claimed high serum testosterone does not increase the risk of prostate cancer [
24]. Prostate growth is very sensitive to changes in androgen concentrations that are well below physiological concentrations but is not sensitive to higher levels of androgen concentrations due to receptor saturation [
25]. A review that included 25 studies found that higher serum testosterone levels were associated with a lower risk of prostate cancer [
2]. A in vitro study showed that low levels of androgens are essential for the growth of prostate cancer cells, while physiological levels or higher inhibit the growth of prostate cancer cells, which may explain the contradiction between androgen deprivation therapy for prostate cancer and the reduced risk of prostate cancer in patients with high testosterone levels [
26]. Therefore, whether testosterone can promote the occurrence and development of prostate cancer is a paradox. Some scholars have proposed a model to explain it: If levels of testosterone below the saturation point, prostate cancer growth would be expected to vary with testosterone concentration. But Exogenous testosterone couldn’t cause any increase of prostate volume or development of prostate cancer in normal men [
27,
28]. Overall, the relationship between testosterone and prostate cancer is complex, and our study supports the hypothesis that testosterone is a risk factor for prostate cancer at the genetic level.
Few studies have investigated sex hormones and gastrointestinal cancer risk. But testosterone has shown different roles in the development of gastrointestinal cancers in existing studies. A large prospective cohort study revealed that testosterone had little association with colorectal cancer and oesophageal squamous cell carcinoma in men [
29]. Our MR study also did not support an association between testosterone and colorectal cancer risk in men. As for stomach cancer, our results suggested a positive association between testosterone and stomach cancer, though a case–control study by Yelda et al. found levels of testosterone were not associated with stomach cancer [
30]. The precise role of testosterone in the stomach is not well understood.
We suspect this may be due to the anti-inflammatory effects of testosterone. It was reported by Jonathan et al. that androgens treatment could suppress the expression of the proinflammatory cytokines by ILC2s. To protect the stomach from spasmolytic polypeptide-expressing metaplasia (SPEM) development [
31]. Chronic SPEM is associated with the development of gastric adenocarcinoma [
32]. The study by Busada et al. also implicated androgens limited IL-33-driven lung inflammation through a cell-intrinsic inhibition of ILC2 expansion. It could well explain why men have lower rates of inflammatory and autoimmune diseases than women. However, Men are twice to third as likely to develop stomach cancer as women, suggesting other factors contribute to disease risk [
33]. So whether testosterone plays a role in the prevention of stomach cancer merits further study. In our study, testosterone might be a risk factor for small intestine cancer. To date, there are few studies on the association between testosterone and small intestine cancer.
Epidemiological studies have shown that men are more likely to develop pancreatic cancer than women, with a male-to-female ratio between 1.25–1.75 and 1, suggesting that sex hormones may play a role in pancreatic cancer [
34]. The presence of androgen receptors in human pancreatic tissue is also well established, and some animal experiments have confirmed that testosterone promotes the growth of pancreatic cancer cells [
35‐
37]. However, none of the several observational studies were able to conclude that testosterone levels are higher in pancreatic cancer patients, and even in a considerable number of studies, testosterone levels were found to be lower in pancreatic cancer patients [
38‐
40]. Moreover, some the other experiments have also shown that dehydroepiandrosterone (DHEA), an androgen precursor, inhibits pancreatic cancer in animal models [
41,
42]. Given the possible effects of androgens on pancreatic cancer, several prospective randomized controlled trials have explored the effects of androgen receptor inhibitors on pancreatic cancer; however, the findings have been inconsistent y[
43,
44]. In addition to their methodological shortcomings, the sample sizes of these RCTs were small, making it difficult to draw reliable conclusions. While our study suggested that a high level of testosterone is a protective factor against pancreatic cancer, more studies are needed in the future to reveal the exact mechanisms.
The main strength of this study is the MR design, which reduces potential bias from confounding factors and reverses causality. Another important advantage is that we assessed the association between testosterone and a wide range of cancers, most of which were not previously examined based on genetic instruments. One limitation is that our analysis included only men of European ancestry, thus limiting the universality of our results to other populations. Another disadvantage is that it was less accurate in analyzing cancers with a limited number of cases (fewer than 1000). More large sample data needs to be included for validation analysis. Finally, we cannot pinpoint the relationship between specific serum testosterone levels and various cancers, which will be fulfilled in later studies.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.